B. Christian

发表

Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.

G. Salles, B. Coiffier, O. Casasnovas, 2001, The hematology journal : the official journal of the European Haematology Association.

Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial.

D. de Jong, E. Noordijk, A. Stamatoullas, 2017, International journal of radiation oncology, biology, physics.

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).

B. Coiffier, O. Casasnovas, H. Tilly, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma ( LNH 03-1 B )

er, O. Casasnovas, H. Tilly, 2013 .

FcγRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP)

P. Gaulard, B. Coiffier, O. Casasnovas, 2004, Leukemia.

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.

B. Coiffier, O. Casasnovas, H. Tilly, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Placebo-Controlled Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myelogenous Leukemia in Elderly Patients

P. Hurteloup, J. Harousseau, Z. Tellier, 1998 .

A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

P. Hurteloup, J. Harousseau, Z. Tellier, 1998, Blood.

Granulocyte-Macrophage Colony-Stimulating Factor During and After Remission Induction Treatment for Elderly Patients with Acute Myeloid Leukemia

C. Gardin, P. Hurteloup, N. Ifrah, 1997 .

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Marc C. Jacob, M. Boubaya, J. Rossi, 2020, Leukemia.

Interferon Alpha and Cytosine Arabinoside in the Treatment of Chronic Myelogenous Leukemia

R. Bouabdallah, F. Bauters, N. Ifrah, 1998 .

Zosteriform cutaneous localizations of B-cell chronic lymphocytic leukaemia.

B. Christian, A. Claeys, F. Truchetet, 2008, European journal of dermatology : EJD.

Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation

B. Christian, C. Rabaud, T. Prazuck, 2010, AIDS.

Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection.

Y. Yazdanpanah, K. Ghomari, B. Christian, 2008, Journal of acquired immune deficiency syndromes.

Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.

B. Christian, C. Rabaud, I. Béguinot, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

P. Gaulard, G. Salles, B. Coiffier, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Severe Strongyloidiasis in AIDS: Is Steroid Therapy Guilty Again?

Y. Yazdanpanah, K. Ghomari, B. Christian, 2008 .

Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients

J. Tamburini, P. Morel, A. Delmer, 2005, Leukemia.

Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV.

Y. Yazdanpanah, B. Christian, C. Rabaud, 2010, AIDS patient care and STDs.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.